Global Somatostatin Analogs Market to Reach $8.5 Billion by 2027

Abstract: - Global Somatostatin Analogs Market to Reach $8. 5 Billion by 2027. - Amid the COVID-19 crisis, the global market for Somatostatin Analogs estimated at US$6 Billion in the year 2020, is projected to reach a revised size of US$8.

New York, May 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Somatostatin Analogs Industry" - https://www.reportlinker.com/p06032950/?utm_source=GNW
5 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Octreotide, one of the segments analyzed in the report, is projected to record a 1.7% CAGR and reach US$2.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Pasireotide segment is readjusted to a revised 8% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 7.8% CAGR
- The Somatostatin Analogs market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 4.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.
- Lanreotide Segment to Record 5.1% CAGR
- In the global Lanreotide segment, USA, Canada, Japan, China and Europe will drive the 4.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$724.9 Million in the year 2020 will reach a projected size of US$999 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.2 Billion by the year 2027, while Latin America will expand at a 6.3% CAGR through the analysis period.

- Select Competitors (Total 43 Featured) -

• Camurus AB

• Chiasma Inc.

• Crinetics Pharmaceuticals

• Dauntless Pharmaceuticals

• Ipsen Pharma

• Midatech Pharma PLC

• Novartis AG

• Peptron, Inc

• Pfizer Inc.

• Sun Pharmaceutical Industries Ltd

• Teva Pharmaceuticals Inc

Read the full report: https://www.reportlinker.com/p06032950/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Somatostatin
Analogs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Somatostatin Analogs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Somatostatin Analogs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Octreotide by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Octreotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Octreotide by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Pasireotide by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Pasireotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Pasireotide by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Lanreotide by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Lanreotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Lanreotide by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Acromegaly by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Acromegaly by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Acromegaly by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Neuroendocrine
Tumors (NETs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Neuroendocrine Tumors
(NETs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Neuroendocrine Tumors
(NETs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 19: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 22: USA Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 23: USA Historic Review for Somatostatin Analogs by Type -
Octreotide, Pasireotide and Lanreotide Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 24: USA 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 25: USA Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 26: USA Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

CANADA
Table 28: Canada Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 29: Canada Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: Canada 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 31: Canada Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: Canada Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 33: Canada 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

JAPAN
Table 34: Japan Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 35: Japan Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: Japan 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 37: Japan Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: Japan Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 39: Japan 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

CHINA
Table 40: China Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: China Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: China 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 43: China Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: China Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: China 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

EUROPE
Table 46: Europe Current & Future Analysis for Somatostatin
Analogs by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 47: Europe Historic Review for Somatostatin Analogs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: Europe 15-Year Perspective for Somatostatin Analogs
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 49: Europe Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 51: Europe 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: Europe Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

FRANCE
Table 55: France Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 56: France Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: France 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 58: France Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: France Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 60: France 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

GERMANY
Table 61: Germany Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: Germany Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: Germany 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 64: Germany Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: Germany Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Germany 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

ITALY
Table 67: Italy Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Italy Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Italy 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 70: Italy Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: Italy Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Italy 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 73: UK Current & Future Analysis for Somatostatin Analogs
by Type - Octreotide, Pasireotide and Lanreotide - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 74: UK Historic Review for Somatostatin Analogs by Type -
Octreotide, Pasireotide and Lanreotide Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 75: UK 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 76: UK Current & Future Analysis for Somatostatin Analogs
by Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 77: UK Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: UK 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

SPAIN
Table 79: Spain Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Spain Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 81: Spain 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 82: Spain Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: Spain Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 84: Spain 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

RUSSIA
Table 85: Russia Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Russia Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Russia 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 88: Russia Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Russia Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Russia 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 91: Rest of Europe Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 92: Rest of Europe Historic Review for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 93: Rest of Europe 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2020 &
2027

Table 94: Rest of Europe Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 95: Rest of Europe Historic Review for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 96: Rest of Europe 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 97: Asia-Pacific Current & Future Analysis for
Somatostatin Analogs by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 98: Asia-Pacific Historic Review for Somatostatin Analogs
by Geographic Region - Australia, India, South Korea and Rest
of Asia-Pacific Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Asia-Pacific 15-Year Perspective for Somatostatin
Analogs by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 100: Asia-Pacific Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 101: Asia-Pacific Historic Review for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2020 &
2027

Table 103: Asia-Pacific Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 104: Asia-Pacific Historic Review for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 105: Asia-Pacific 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2020 & 2027

AUSTRALIA
Table 106: Australia Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Australia Historic Review for Somatostatin Analogs
by Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 108: Australia 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2020 &
2027

Table 109: Australia Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: Australia Historic Review for Somatostatin Analogs
by Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 111: Australia 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2020 & 2027

INDIA
Table 112: India Current & Future Analysis for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 113: India Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 114: India 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2020 & 2027

Table 115: India Current & Future Analysis for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 116: India Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 117: India 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2020 & 2027

SOUTH KOREA
Table 118: South Korea Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 119: South Korea Historic Review for Somatostatin Analogs
by Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 120: South Korea 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2020 &
2027

Table 121: South Korea Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 122: South Korea Historic Review for Somatostatin Analogs
by Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 123: South Korea 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2020 & 2027

REST OF ASIA-PACIFIC
Table 124: Rest of Asia-Pacific Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 125: Rest of Asia-Pacific Historic Review for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 126: Rest of Asia-Pacific 15-Year Perspective for
Somatostatin Analogs by Type - Percentage Breakdown of Value
Sales for Octreotide, Pasireotide and Lanreotide for the Years
2012, 2020 & 2027

Table 127: Rest of Asia-Pacific Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 128: Rest of Asia-Pacific Historic Review for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 129: Rest of Asia-Pacific 15-Year Perspective for
Somatostatin Analogs by Application - Percentage Breakdown of
Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications for the Years 2012, 2020 & 2027

LATIN AMERICA
Table 130: Latin America Current & Future Analysis for
Somatostatin Analogs by Geographic Region - Argentina, Brazil,
Mexico and Rest of Latin America Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 131: Latin America Historic Review for Somatostatin
Analogs by Geographic Region - Argentina, Brazil, Mexico and
Rest of Latin America Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 132: Latin America 15-Year Perspective for Somatostatin
Analogs by Geographic Region - Percentage Breakdown of Value
Sales for Argentina, Brazil, Mexico and Rest of Latin America
Markets for Years 2012, 2020 & 2027

Table 133: Latin America Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 134: Latin America Historic Review for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 135: Latin America 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2020 &
2027

Table 136: Latin America Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 137: Latin America Historic Review for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032950/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001